Table 4: Treatment of patients with disease progression.
Patient | Origin | Risk group (AFIP-Miettinen8) | Adjuvant Imatinib (months) | Recurrence time (months) | Recurrence site | Treatment for progression | Follow-up (months) | Outcome |
1) | Small intestine | Intermediate | No | 40 | Local recurrence | Surgical resection and imatinib | 60 | AWD |
2) | Small intestine | High | 24 | 24 | Peritoneal dissemination | Surgical resection and imatinib | 36 | AD |
3) | Small intestine | High | 24 | 28 | Peritoneal dissemination | Surgical resection and imatinib | 48 | AD |
4) | Small intestine | Intermediate | 36 | 40 | Local recurrence | Surgical resection and imatinib | 55 | AWD |
5) | Small intestine | High | 24 | 36 | Local recurrence | Surgical resection and imatinib | 60 | AD |
6) | Stomach | High | 18 | 18 | Liver | Imatinib | 41 | DD |
AWD: Alive without disease; DD: Died of disease; AD: Alive with disease.